Vise Technologies Inc. Buys Shares of 23,309 Dynavax Technologies Corporation $DVAX

Vise Technologies Inc. purchased a new stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,309 shares of the biopharmaceutical company’s stock, valued at approximately $231,000.

A number of other large investors have also modified their holdings of the company. Choreo LLC boosted its stake in Dynavax Technologies by 3.2% during the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company’s stock valued at $452,000 after purchasing an additional 1,065 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Dynavax Technologies by 4.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company’s stock valued at $401,000 after purchasing an additional 1,453 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Dynavax Technologies by 1.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock valued at $1,126,000 after buying an additional 1,625 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Dynavax Technologies by 5,485.7% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,304 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Dynavax Technologies by 0.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,157,993 shares of the biopharmaceutical company’s stock worth $15,019,000 after buying an additional 2,913 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

Insiders Place Their Bets

In other Dynavax Technologies news, Director Scott Dunseth Myers acquired 3,800 shares of Dynavax Technologies stock in a transaction dated Friday, August 22nd. The stock was bought at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the transaction, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This trade represents a 12.18% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.98% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on DVAX shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Wall Street Zen raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a report on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, Dynavax Technologies presently has an average rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Stock Up 0.7%

Shares of DVAX stock opened at $11.14 on Tuesday. Dynavax Technologies Corporation has a 1 year low of $9.20 and a 1 year high of $14.63. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The business’s fifty day moving average is $10.16 and its 200-day moving average is $10.28. The stock has a market cap of $1.31 billion, a PE ratio of -24.22 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. Equities analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.